ReviewFrontiers in oncology2022

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.

Thomas Yul Avery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.